Results 141 to 150 of about 23,326 (221)

Incidence of Type 1 Inflammation-associated Diseases in Atopic Children Treated with Dupilumab [PDF]

Stanislaw J. Gabryszewski, Kathryn Hirabayashi, Morgan Botdorf, Mitchell Maltenfort, Christopher B. Forrest, Jonathan Spergel   +5 more
openalex   +1 more source

Effectiveness and Safety of Dupilumab in Children Under 6 Years of Age with Moderate-to-Severe Atopic Dermatitis: A Retrospective Real-World Study

, 2023
Emilio Berná‐Rico, Esther Fiz Benito, José Manuel Busto‐Leis, Guillermo Servera-Negre, R. de Lucas‐Laguna, Marta Feito Rodríguez   +5 more
openalex   +2 more sources

Parallel Inhibition of Interleukin 4 (IL-4)/Interleukin 13 (IL-13) and Janus Kinase 1 (JAK1) in Atopic Dermatitis: Beyond the Traditional Biologic Paradigm. [PDF]

Cureus
Perez-Romero AG, Rangel MA, Crocker Sandoval AB, Ruiz Leon M, Aceves M.   +4 more
europepmc   +1 more source

Paradoxical lichenoid drug eruption following dupilumab use for atopic dermatitis: A case report. [PDF]

SAGE Open Med Case Rep
Gandhi M, Vanderbeck K, Giroux L.
europepmc   +1 more source

Reassuring evidence on infection risk with dupilumab in atopic dermatitis: Lessons from real-world evidence. [PDF]

J Eur Acad Dermatol Venereol
van der Gang LF, de Bruin-Weller MS.
europepmc   +1 more source

Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index

, 2019
Lieneke F.M. Ariëns, Abhijit Gadkari, Harmieke van Os‐Medendorp, Rajeev Ayyagari, Emi Terasawa, Andreas Kuznik, Zhen Chen, Gaëlle Bégo-Le Bagousse, Yufang Lü, E. Rizova, Neil M.H. Graham, Gianluca Pirozzi, Marjolein de Bruin‐Weller, Laurent Eckert   +13 more
openalex   +2 more sources

Serum IL-13 and IL-31 Levels are not Attenuated upon Dupilumab Treatment: Lessons from a Prospective Cohort.

Acta Derm Venereol
Suleiman G, Boyango I, Dawood M, Mirmovitch-Morvay O, Avitan-Hersh E.   +4 more
europepmc   +1 more source

Omalizumab to dupilumab switch in chronic spontaneous urticaria. [PDF]

World Allergy Organ J
Özdemir Ö.
europepmc   +1 more source

High Remission Rate in Eosinophilic Chronic Rhinosinusitis Following More Than Two Years of Dupilumab Therapy. [PDF]

Laryngoscope Investig Otolaryngol
Kamimura S, Ishitani K, Morozumi R, Fujii T, Kitamura Y.   +4 more
europepmc   +1 more source

Real-World Assessment of Dupilumab in Chinese Atopic Dermatitis Patients: Efficacy, Safety, and Impact of Comorbidities. [PDF]

J Asthma Allergy
Zhang P, Chen H, Huang N, Li W, Yang Y, Ma D, Fu Y, Liu J, Xu Q, Li L, Zhu R.   +10 more
europepmc   +1 more source